Equipo ISGlobal

Andrea Alemany is a postdoctoral researcher at the Barcelona Institute for Global Health (ISGlobal), Spain. She completed her Family Medicine training in 2019, earned a diploma in Tropical Medicine and Hygiene from the London School of Hygiene and Tropical Medicine in 2023, and obtained her PhD from the University of Barcelona in 2024.

From 2020 to 2024, Andrea worked as both a researcher and consultant in the STI unit at Fight Infectious Diseases Foundation and Germans Trias i Pujol University Hospital. Her research has focused on advancing diagnostics and early treatments for emerging viral diseases, using affordable and widely available tools. She has extensive experience in designing and coordinating large clinical studies during viral epidemics. Her PhD findings had global implications for the use of passive immunotherapies, including convalescent plasma and hyperimmune immunoglobulins, for COVID-19. Her findings during the 2022 mpox outbreak informed international infection prevention and control policies. Additionally, she contributed to research aimed at improving diagnostic and treatment strategies for yaws and syphilis in Ghana and Papua New Guinea. 

She aims to focus her postdoctoral research on evaluating novel prognostic tools based on host response biomarkers to enhance triage and risk stratification of emerging viral diseases.

Líneas de investigación

• Early treatment and prevention of COVID-19 using passive immunotherapies, including convalescent plasma and hyperimmune immunoglobulins.
• Evaluation of rapid point-of-care diagnostic tools for COVID-19.
• Characterization of clinical presentation, epidemiology, viral clearance, immune responses, and vaccine efficacy during mpox global outbreak.
• Novel biomarker-based prognostic tools to enhance risk stratification of emerging viral diseases.
• Novel biomarker-based prognostic tools to enhance triage and risk stratification of children with febrile illnesses in Sub-Saharan Africa.

Principales publicaciones

• Alemany A (CA), et al. et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respir Med. 2022 Mar;10(3):278-288.  
• Mitjà O*, Alemany A*, Marks M*, et al. Mpox in people with advanced HIV infection: a global case series. Lancet. 2023 Feb 20:S0140-6736(23)00273-8. 
• Alemany A (CA), et al. Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trial. EClinicalMedicine. 2023 Mar 10;57:101898. 
• Millat-Martinez P*, Gharbharan A*, Alemany A*, et al. Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients. Nat Commun. 2022 May 11;13(1):2583. 
• Tarín-Vicente EJ, Alemany A, et al. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study. Lancet. 2022 Aug 27;400(10353):661-669. 
•  Alemany A, et al. Analytical and clinical performance of the panbio COVID-19 antigen-detecting rapid diagnostic test. J Infect. 2021 Jan 7:S0163-4453(21)00004-9.